Safety Profiles and Proactive Adverse Event Management

Dr. Gumbleton reviews the distinct safety profiles of the two combination regimens with attention to Mrs. Chen's concern about visible skin-related side effects in front of her students.

The amivantamab-plus-lazertinib regimen is associated primarily with cutaneous adverse effects and a venous thromboembolism (VTE) risk, the latter substantially mitigated by prophylactic anticoagulation in all patients at initiation. Cutaneous toxicity is improved by a proactive supportive care regimen studied with amivantamab that includes an oral antibiotic, topical lotion, and chlorhexidine for the nails.

Even with prophylaxis, some cutaneous adverse events still occur. Dr. Gumbleton emphasizes counseling Mrs. Chen to report effects at the earliest sign. Management includes intensifying supportive care, temporarily pausing amivantamab, or dose reduction, with data supporting that patients who interrupt or dose-reduce for cutaneous toxicity do as well as those continuing at full dose. Cutaneous adverse effects typically improve over time.

The adverse effects of the FLAURA2 regimen are driven largely by the chemotherapy component and include hematologic toxicity, most notably neutropenic fever, a concern amplified by Mrs. Chen's daily exposure to school-aged children. Chemotherapy-related adverse effects tend to worsen with cumulative cycles, with fatigue in particular catching up over time. In contrast, cutaneous toxicity with amivantamab plus lazertinib is most pronounced early and tends to improve with continued treatment—a short-term versus long-term tolerability trade-off between the two regimens.

In the next episode, “Treatment Burden, Clinic Visits, and the Subcutaneous Amivantamab Formulation,” Dr. Gumbleton translates administration logistics into what they mean for Mrs. Chen.